ER-resident selenoproteins such as SELENOS and SELENOK arouse particular interest, as they are supposed to modulate inflammatory processes, oxidative stress, and ERS; these are emerging as critical determinants in T2D settings, and therefore, may act as potential pharmacological targets [179]. This evidence concerns the gene SELENOS and type 2 diabetes mellitus.